Metastatic Bladder Urothelial Carcinoma Clinical Trials

17 clinical trials for Metastatic Bladder Urothelial Carcinoma across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors — RECRUITING · PHASE2
• Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers — RECRUITING · PHASE2
• Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform — RECRUITING
• Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial — RECRUITING · PHASE4
• Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy — ACTIVE_NOT_RECRUITING · PHASE1
• Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer — COMPLETED · PHASE3
• Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study — ACTIVE_NOT_RECRUITING · PHASE3
• ARID1A and/or KDM6A Mutation and CXCL13 Expression — ACTIVE_NOT_RECRUITING · PHASE2
• Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy — ACTIVE_NOT_RECRUITING · PHASE3
• Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate — ACTIVE_NOT_RECRUITING · PHASE1
• Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer — COMPLETED · PHASE2
• Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma — COMPLETED · PHASE2
• Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy — WITHDRAWN · PHASE2

Refine this search